Folio Search · free preview

Papers on “HPV vaccine cervical cancer prevention”

Live results from Semantic Scholar, CrossRef and OpenAlex. No account needed to look.

1. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis

   Zhuoru Zou, Christopher Kincaid Fairley, Jason J. Ong, et al. · 2020 · The Lancet Global Health · 175 cites

   BACKGROUND: Coinciding with the release of the first Chinese domestic human papillomavirus (HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer screening technology, we aimed to evaluate the cost-effectiveness of the combined strategies of cervical cancer screening programmes and universal vaccination of girls (aged 9-14 years) with Cecolin in China. METHODS: We did a cost-effectiveness analysis in China, in which we developed a Markov model of cervical cancer to evaluate the incremental cost-effectiveness ratios of 61 intervention strategies, including a combination of various screening methods at different frequencies with and without vaccination, and also vac

   Save to my library →

2. Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines

   Fabián Méndez, Núbia Muñóz, Héctor Posso, et al. · 2005 · The Journal of Infectious Diseases · 161 cites

   Coinfection with multiple types of human papillomavirus (HPV) and its implications for the development of efficacious HPV vaccines is a subject of great interest. To describe the occurrence of concurrent infection with multiple HPV types and to determine whether genital HPV infection modifies the risk of acquiring a new HPV infection with another HPV type, 1610 subjects were monitored for an average of 4.1 years in Bogota, Colombia. Information on risk factors for HPV infection and cervical cells was collected for detection of HPV DNA of 36 types at study entry and at 6 consecutive 6-month follow-up visits. Clustering or the concurrent acquisition of multiple types occurred more often than w

   Save to my library →

3. Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer

   Tzyy-Choou Wu · 2008 · Biologics · 139 cites

   Cervical cancer continues to be the second largest cause of cancer deaths in women worldwide. Persistent infection with high-risk types of human papillomavirus (HPV) is a necessary cause of cervical cancer. Thus, prophylactic vaccination against HPV is an attractive strategy to prevent cervical cancer. Current strategies for the development of safe and effective preventive vaccines are based on the induction of neutralizing antibodies against the major capsid protein, L1 of HPV. Cervarix() is one of the preventive HPV vaccines that has been approved in the Europe and Australia and is currently under review by the US Food and Drug Administration. Cervarix is composed of HPV16 and HPV18 L1 vir

   Save to my library →

4. A qualitative analysis of South African women's knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health.

   S. Francis, M. Battle-Fisher, J. Liverpool, et al. · 2011 · Vaccine · 98 cites

   Save to my library →

5. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

   David Jenkins · 2008 · Gynecologic Oncology · 84 cites

   Save to my library →

6. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool

   R. Hutubessy, A. Levin, Susan A. Wang, et al. · 2012 · BMC Medicine · 64 cites

   BackgroundThe purpose, methods, data sources and assumptions behind the World Health Organization (WHO) Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to assist low- and middle-income countries (LMICs) with planning and costing their nationwide human papillomavirus (HPV) vaccination program are presented. Tanzania is presented as a case study where the WHO C4P tool was used to cost and plan the roll-out of HPV vaccines nationwide as part of the national comprehensive cervical cancer prevention and control strategy.MethodsThe WHO C4P tool focuses on estimating the incremental costs to the health system of vaccinating adolescent girls through school-, health facil

   Save to my library →

7. Prevention strategies of cervical cancer in the HPV vaccine era

   Xavier F. Bosch, Diane Medved Harper · 2006 · Gynecologic Oncology · 64 cites

   Save to my library →

8. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

   S. Skinner, D. Apter, N. D. de Carvalho, et al. · 2016 · Expert Review of Vaccines · 54 cites

   ABSTRACT Vaccines are available against human papillomavirus (HPV), the causal agent of cervical and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial program were reviewed. Six randomized, controlled phase II/III trials evaluating cervical endpoints enrolled women from diverse populations and geographical locations. The program analyzed extensively the cohorts most relevant from a public health perspective: the total vaccinated cohort (TVC), approximating a general population including those with existing or previous HPV infection, and TVC-naïve, approximating a population of young women before sexual debut. Results show that the vaccine reduces HPV-16/1

   Save to my library →